HRP20000182B1 - Postupci i međuprodukti u pripravi antikancerogenih spojeva - Google Patents

Postupci i međuprodukti u pripravi antikancerogenih spojeva

Info

Publication number
HRP20000182B1
HRP20000182B1 HR20000182A HRP20000182A HRP20000182B1 HR P20000182 B1 HRP20000182 B1 HR P20000182B1 HR 20000182 A HR20000182 A HR 20000182A HR P20000182 A HRP20000182 A HR P20000182A HR P20000182 B1 HRP20000182 B1 HR P20000182B1
Authority
HR
Croatia
Prior art keywords
alkyl
intermediates
processes
alkoxy
compound
Prior art date
Application number
HR20000182A
Other languages
English (en)
Inventor
Shelton Lehner Richard
Norris Tymothy
Paul Santafianos Dinos
Original Assignee
Pfizer Products Inc.
Osi Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc., Osi Pharmaceuticals filed Critical Pfizer Products Inc.
Publication of HRP20000182A2 publication Critical patent/HRP20000182A2/hr
Publication of HRP20000182B1 publication Critical patent/HRP20000182B1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
    • C22B—PRODUCTION AND REFINING OF METALS; PRETREATMENT OF RAW MATERIALS
    • C22B15/00—Obtaining copper
    • C22B15/0002—Preliminary treatment
    • C22B15/0004—Preliminary treatment without modification of the copper constituent
    • C—CHEMISTRY; METALLURGY
    • C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
    • C22B—PRODUCTION AND REFINING OF METALS; PRETREATMENT OF RAW MATERIALS
    • C22B15/00—Obtaining copper
    • C22B15/0063—Hydrometallurgy
    • C22B15/0065—Leaching or slurrying
    • C22B15/0067—Leaching or slurrying with acids or salts thereof
    • C22B15/0071—Leaching or slurrying with acids or salts thereof containing sulfur
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P10/00—Technologies related to metal processing
    • Y02P10/20—Recycling

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Manufacturing & Machinery (AREA)
  • Materials Engineering (AREA)
  • Mechanical Engineering (AREA)
  • Metallurgy (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Postupak dobivanja spoja formule I: ili farmaceutski prihvatljive soli ili solvata navedenog spoja,gdje: svakog od R1 i R2 se neovisno bira između C1-C10 alkila i C1-C10 alkoksi, gdje navedeni alkili alkoksi su izborno supstituirani s do 2 supstituenta, koje se neovisno bira između hidroksi i C1-C6 alkoksi; R15 je H, C1-C10 alkil ili -(CH2)q(C6-C10 aril), gdje q je cijeli broj od 0 do 4; naznačen time što se sastoji u obradi spoja formule 2gdje R15, R1 i R2 su definirani gore, a G je blokirajuća skupina -C(OH)R3R4;svaki od R3 i R4 je neovisno C1-C6 alkil; s alkalnim metalom ili hidroksidom alkalnog metala, u otapalu kojeg čini hidroksi-supstituirani C1-C10 alkil. Patent sadrži još 12 patentnih zahtjeva.
HR20000182A 1999-03-31 2000-03-31 Postupci i međuprodukti u pripravi antikancerogenih spojeva HRP20000182B1 (hr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12707299P 1999-03-31 1999-03-31

Publications (2)

Publication Number Publication Date
HRP20000182A2 HRP20000182A2 (en) 2001-04-30
HRP20000182B1 true HRP20000182B1 (hr) 2007-10-31

Family

ID=22428179

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20000182A HRP20000182B1 (hr) 1999-03-31 2000-03-31 Postupci i međuprodukti u pripravi antikancerogenih spojeva

Country Status (50)

Country Link
US (1) US6476040B1 (hr)
EP (1) EP1044969B1 (hr)
JP (2) JP3420549B2 (hr)
KR (2) KR100430210B1 (hr)
CN (2) CN1215061C (hr)
AP (2) AP1265A (hr)
AR (1) AR018705A1 (hr)
AT (1) ATE348098T1 (hr)
AU (2) AU781402B2 (hr)
BG (1) BG65194B1 (hr)
BR (1) BRPI0001486B8 (hr)
CA (2) CA2302965C (hr)
CO (1) CO5160273A1 (hr)
CR (1) CR6165A (hr)
CZ (1) CZ299426B6 (hr)
DE (1) DE60032275T2 (hr)
DK (1) DK1044969T3 (hr)
DZ (1) DZ3030A1 (hr)
EA (3) EA005892B1 (hr)
EE (1) EE04589B1 (hr)
EG (1) EG22506A (hr)
ES (1) ES2278578T3 (hr)
GE (1) GEP20022653B (hr)
GT (1) GT200000037A (hr)
HK (1) HK1029790A1 (hr)
HR (1) HRP20000182B1 (hr)
HU (1) HU227698B1 (hr)
ID (1) ID25427A (hr)
IL (2) IL168036A (hr)
IS (1) IS2468B (hr)
MA (1) MA25087A1 (hr)
MY (1) MY136270A (hr)
NO (2) NO321952B1 (hr)
NZ (2) NZ503683A (hr)
OA (1) OA11335A (hr)
PA (1) PA8491901A1 (hr)
PE (1) PE20001599A1 (hr)
PL (1) PL339330A1 (hr)
PT (1) PT1044969E (hr)
RS (1) RS49836B (hr)
SG (2) SG115536A1 (hr)
SK (1) SK287339B6 (hr)
SV (1) SV2002000047A (hr)
TN (1) TNSN00064A1 (hr)
TR (1) TR200000837A2 (hr)
TW (1) TW553939B (hr)
UA (2) UA70928C2 (hr)
UY (1) UY26086A1 (hr)
YU (1) YU13200A (hr)
ZA (1) ZA200001586B (hr)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6706721B1 (en) 1998-04-29 2004-03-16 Osi Pharmaceuticals, Inc. N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
UA74803C2 (uk) * 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
US7087613B2 (en) 1999-11-11 2006-08-08 Osi Pharmaceuticals, Inc. Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
ATE355275T1 (de) 2000-10-20 2006-03-15 Eisai R&D Man Co Ltd Stickstoff-enthaltende aromatische ringverbindungen zur behandlung von tumorerkrankungen
EP1408980A4 (en) 2001-06-21 2004-10-20 Ariad Pharma Inc NEW QUINAZOLINES AND THEIR USE
US7078409B2 (en) 2002-03-28 2006-07-18 Beta Pharma, Inc. Fused quinazoline derivatives useful as tyrosine kinase inhibitors
US7576074B2 (en) 2002-07-15 2009-08-18 Rice Kenneth D Receptor-type kinase modulators and methods of use
US7148231B2 (en) * 2003-02-17 2006-12-12 Hoffmann-La Roche Inc. [6,7-Bis(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)amine hydrochloride polymorph
JPWO2004080462A1 (ja) 2003-03-10 2006-06-08 エーザイ株式会社 ｃ−Ｋｉｔキナーゼ阻害剤
US8309562B2 (en) * 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
CN1984660B (zh) 2003-07-03 2010-12-15 美瑞德生物工程公司 作为天冬氨酸特异性半胱氨酸蛋白酶活化剂和细胞程序死亡诱导剂的4-芳基氨基-喹唑啉
RU2378268C2 (ru) 2003-09-16 2010-01-10 Астразенека Аб Производные хиназолина в качестве ингибиторов тирозинкиназы
PL2213661T3 (pl) 2003-09-26 2011-12-30 Exelixis Inc Modulatory c-Met i sposoby ich zastosowania
US7683172B2 (en) 2003-11-11 2010-03-23 Eisai R&D Management Co., Ltd. Urea derivative and process for preparing the same
KR20080095915A (ko) 2004-05-06 2008-10-29 워너-램버트 캄파니 엘엘씨 4-페닐아미노-퀴나졸린-6-일-아미드
JP4834553B2 (ja) 2004-09-17 2011-12-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 医薬組成物
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
EP1833482A4 (en) 2005-01-03 2011-02-16 Myriad Genetics Inc COMPOUNDS AND ITS THERAPEUTIC USE
US7625911B2 (en) * 2005-01-12 2009-12-01 Mai De Ltd. Amorphous form of erlotinib hydrochloride and its solid amorphous dispersion
CA2599115A1 (en) 2005-02-28 2006-08-31 Eisai R & D Management Co., Ltd. Novel combinational use of sulfonamide compound
WO2007015569A1 (ja) * 2005-08-01 2007-02-08 Eisai R & D Management Co., Ltd. 血管新生阻害物質の効果を予測する方法
EP1925676A4 (en) 2005-08-02 2010-11-10 Eisai R&D Man Co Ltd TEST METHOD FOR THE EFFECT OF A VASCULARIZATION INHIBITOR
EP1949902B1 (en) * 2005-11-07 2012-06-27 Eisai R&D Management Co., Ltd. USE OF COMBINATION OF ANTI-ANGIOGENIC SUBSTANCE AND c-kit KINASE INHIBITOR
US20090247576A1 (en) * 2005-11-22 2009-10-01 Eisai R & D Management Co., Ltd. Anti-tumor agent for multiple myeloma
RU2448708C3 (ru) * 2006-05-18 2017-09-28 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Противоопухолевое средство против рака щитовидной железы
US20090203693A1 (en) * 2006-06-29 2009-08-13 Eisai R & D Management Co., Ltd. Therapeutic agent for liver fibrosis
CA2659307A1 (en) 2006-07-28 2008-01-31 Synthon B.V. Crystalline erlotinib
CN101511793B (zh) 2006-08-28 2011-08-03 卫材R&D管理有限公司 针对未分化型胃癌的抗肿瘤剂
US8372856B2 (en) 2006-10-27 2013-02-12 Synthon Bv Hydrates of erlotinib hydrochloride
AU2008205847A1 (en) 2007-01-19 2008-07-24 Eisai R & D Management Co., Ltd. Composition for treatment of pancreatic cancer
KR101445892B1 (ko) 2007-01-29 2014-09-29 에자이 알앤드디 매니지먼트 가부시키가이샤 미분화형 위암 치료용 조성물
WO2008102369A1 (en) 2007-02-21 2008-08-28 Natco Pharma Limited Novel polymorphs of erlotinib hydrochloride and method of preparation
JP5524041B2 (ja) 2007-04-04 2014-06-18 シプラ・リミテッド エルロチニブおよびその薬学的に許容可能な塩の製造方法
US20090012295A1 (en) * 2007-06-25 2009-01-08 Ales Gavenda Amorphous Erlotinib, processes for the preparation thereof, and processes to prepare additional forms of Erlotinib
ES2492645T3 (es) 2007-07-11 2014-09-10 Hetero Drugs Limited Un procedimiento mejorado para la preparación de hidrocloruro de erlotinib
WO2009025875A1 (en) * 2007-08-23 2009-02-26 Plus Chemicals Sa Stable formulations of crystalline erlotinib hcl
US20090124642A1 (en) * 2007-08-23 2009-05-14 Augusto Canavesi Crystalline forms of Erlotinib HCI and formulations thereof
US20090076042A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched erlotinib
CN101848895B (zh) 2007-11-09 2013-10-23 卫材R&D管理有限公司 血管新生抑制物质和抗肿瘤性铂络合物的组合使用
BRPI0906576A2 (pt) * 2008-01-29 2015-07-07 Eisai R&D Man Co Ltd Composição farmacêutica, kit, uso de um composto, e, agente terapêutico para câncer
WO2009121042A1 (en) * 2008-03-28 2009-10-01 Concert Pharmaceuticals, Inc. Quinazoline derivatives and methods of treatment
CA2730226A1 (en) * 2008-07-07 2010-01-14 Plus Chemicals Sa Crystalline forms of erlotinib base and erlotinib hcl
KR101132937B1 (ko) 2008-10-01 2012-04-06 주식회사종근당 Ｎ-(3-에티닐페닐)-6,7-비스(2-메톡시에톡시)-4-퀴나졸린아민 납실레이트 염
WO2010040212A1 (en) * 2008-10-08 2010-04-15 Apotex Pharmachem Inc. Processes for the preparation of erlotinib hydrochloride
TWI447108B (zh) 2009-01-16 2014-08-01 Exelixis Inc Ｎ－（４－｛〔６，７雙（甲氧基）喹啉－４－基〕氧基｝苯基）－ｎ’－（４－氟苯基）環丙烷－１，１－二甲醯胺之蘋果酸鹽及其結晶型
EP2411373B1 (en) 2009-03-26 2015-10-21 Ranbaxy Laboratories Limited Process for the preparation of erlotinib or its pharmaceutically acceptable salts thereof
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
EP2499118A2 (en) 2009-11-12 2012-09-19 Ranbaxy Laboratories Limited Processes for the preparation of erlotinib hydrochloride form a and erlotinib hydrochloride form b
WO2011068404A2 (en) 2009-12-02 2011-06-09 Ultimorphix Technologies B.V. Administration of n-(3-ethynylphenylamino)-6,7-bis(2- methoxyethoxy)-4-quinazolinamine mesylate salt by inhalation
ES2573515T3 (es) 2010-06-25 2016-06-08 Eisai R&D Management Co., Ltd. Agente antitumoral que emplea compuestos con efecto inhibitorio de cinasas combinados
NZ606042A (en) 2010-07-23 2015-05-29 Generics Uk Ltd Process for the preparation of erlotinib and salts thereof
IT1402029B1 (it) * 2010-10-14 2013-08-28 Italiana Sint Spa Procedimento per la preparazione di erlotinib
US8962650B2 (en) 2011-04-18 2015-02-24 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
US9945862B2 (en) 2011-06-03 2018-04-17 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
CN102267952B (zh) * 2011-06-21 2013-12-11 天津市汉康医药生物技术有限公司 喹唑啉类化合物、其制备方法和用途
CN103420924B (zh) * 2012-05-25 2016-08-31 浙江九洲药业股份有限公司 一种盐酸埃罗替尼晶型a的制备方法
WO2014037961A1 (en) 2012-09-04 2014-03-13 Shilpa Medicare Limited Crystalline erlotinib hydrochloride process
WO2014098176A1 (ja) 2012-12-21 2014-06-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 キノリン誘導体のアモルファス及びその製造方法
WO2014118737A1 (en) 2013-01-31 2014-08-07 Ranbaxy Laboratories Limited Erlotinib salts
AU2014266223B2 (en) 2013-05-14 2020-06-25 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
CN103333124B (zh) * 2013-05-28 2015-03-25 埃斯特维华义制药有限公司 一种制备盐酸厄洛替尼晶型f的方法
EP3825305A1 (en) 2014-08-28 2021-05-26 Eisai R&D Management Co., Ltd. Process for preparing lenvatinib
CA2908441A1 (en) 2014-10-28 2016-04-28 Cerbios-Pharma Sa Process for the preparation of erlotinib
JP6792546B2 (ja) 2015-02-25 2020-11-25 エーザイ・アール・アンド・ディー・マネジメント株式会社 キノリン誘導体の苦味抑制方法
KR20240064733A (ko) 2015-03-04 2024-05-13 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
WO2016204193A1 (ja) 2015-06-16 2016-12-22 株式会社ＰＲＩＳＭ Ｐｈａｒｍａ 抗がん剤
CN105884653A (zh) * 2016-06-08 2016-08-24 浙江汇能生物股份有限公司 一种埃罗替尼衍生物及其制备方法
CN106279585A (zh) * 2016-08-26 2017-01-04 宁波圣达精工智能科技有限公司 一种阻燃智能密集书架的制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4747498A (en) * 1986-06-27 1988-05-31 Sunbeam Plastics Corporation Safety dispensing closure-container package
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
JP2657760B2 (ja) * 1992-07-15 1997-09-24 小野薬品工業株式会社 ４−アミノキナゾリン誘導体およびそれを含有する医薬品
ES2332984T3 (es) * 1995-03-30 2010-02-16 Pfizer Products Inc. Derivados de quinazolinas.
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
CN1125817C (zh) 1996-02-13 2003-10-29 曾尼卡有限公司 作为vegf抑制剂的喹唑啉衍生物
NZ331191A (en) 1996-03-05 2000-03-27 Zeneca Ltd 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
US6225499B1 (en) 1997-07-14 2001-05-01 Catalytica Pharmaceuticals, Inc. Process for preparing aminoarylacetylenes
AU759691C (en) 1998-04-29 2004-04-29 Osi Pharmaceuticals, Inc. N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4- quinazolinamine mesylate anhydrate and monohydrate

Also Published As

Publication number Publication date
UA70928C2 (uk) 2004-11-15
CN100351242C (zh) 2007-11-28
CO5160273A1 (es) 2002-05-30
EE04589B1 (et) 2006-02-15
JP4074509B2 (ja) 2008-04-09
NO20054715L (no) 2000-10-02
NO20001648D0 (no) 2000-03-30
EA004654B1 (ru) 2004-06-24
IS2468B (is) 2008-12-15
EE200000255A (et) 2000-12-15
OA11335A (en) 2003-12-10
CN1276370A (zh) 2000-12-13
BRPI0001486B8 (pt) 2021-05-25
CZ20001155A3 (cs) 2001-03-14
UA80955C2 (en) 2007-11-26
MY136270A (en) 2008-09-30
DZ3030A1 (fr) 2004-03-27
EA200000274A2 (ru) 2000-10-30
JP2000290262A (ja) 2000-10-17
IS5411A (is) 2000-10-02
CN1215061C (zh) 2005-08-17
HUP0001353A2 (hu) 2001-05-28
EA200201245A1 (ru) 2003-04-24
HU227698B1 (en) 2011-12-28
CN1699350A (zh) 2005-11-23
NO20001648L (no) 2000-10-02
CA2302965C (en) 2004-02-17
GEP20022653B (en) 2002-03-25
RS49836B (sr) 2008-08-07
KR100430209B1 (ko) 2004-05-03
BG104278A (en) 2001-08-31
DE60032275D1 (de) 2007-01-25
CA2302965A1 (en) 2000-09-30
PL339330A1 (en) 2000-10-09
NZ503683A (en) 2001-09-28
AU2005201494A1 (en) 2005-05-05
EP1044969B1 (en) 2006-12-13
YU13200A (sh) 2002-10-18
UY26086A1 (es) 2000-10-31
SK4442000A3 (en) 2000-10-09
KR100430210B1 (ko) 2004-05-03
SG121687A1 (en) 2006-05-26
AU2005201494B2 (en) 2008-02-07
HK1029790A1 (en) 2001-04-12
US6476040B1 (en) 2002-11-05
JP3420549B2 (ja) 2003-06-23
SV2002000047A (es) 2002-01-23
TR200000837A2 (tr) 2000-11-21
IL135245A0 (en) 2001-05-20
ATE348098T1 (de) 2007-01-15
AP1655A (en) 2006-09-01
EP1044969A3 (en) 2000-11-29
SK287339B6 (sk) 2010-07-07
BG65194B1 (bg) 2007-06-29
DK1044969T3 (da) 2007-04-23
KR20020084903A (ko) 2002-11-13
EA200000274A3 (ru) 2003-02-27
TW553939B (en) 2003-09-21
PT1044969E (pt) 2007-05-31
AP1265A (en) 2004-03-26
BRPI0001486B1 (pt) 2019-01-29
PA8491901A1 (es) 2001-12-14
ES2278578T3 (es) 2007-08-16
PE20001599A1 (es) 2001-01-18
AU781402B2 (en) 2005-05-19
HUP0001353A3 (en) 2002-01-28
EA005561B1 (ru) 2005-04-28
SG115536A1 (en) 2005-10-28
AR018705A1 (es) 2001-11-28
IL168036A (en) 2006-12-10
ID25427A (id) 2000-10-05
KR20010014658A (ko) 2001-02-26
EA200201244A1 (ru) 2003-04-24
CA2427221A1 (en) 2000-09-30
HRP20000182A2 (en) 2001-04-30
NO324745B1 (no) 2007-12-03
TNSN00064A1 (fr) 2005-11-10
CZ299426B6 (cs) 2008-07-23
EG22506A (en) 2003-03-31
EP1044969A2 (en) 2000-10-18
NZ512818A (en) 2003-01-31
CR6165A (es) 2008-10-10
NO321952B1 (no) 2006-07-24
GT200000037A (es) 2001-09-21
CA2427221C (en) 2008-09-16
JP2003176274A (ja) 2003-06-24
MA25087A1 (fr) 2000-10-01
HU0001353D0 (en) 2000-06-28
DE60032275T2 (de) 2007-07-12
BR0001486A (pt) 2001-05-02
AP2000001778A0 (en) 2000-03-31
AU2262000A (en) 2000-10-05
ZA200001586B (en) 2001-10-01
EA005892B1 (ru) 2005-06-30

Similar Documents

Publication Publication Date Title
HRP20000182B1 (hr) Postupci i međuprodukti u pripravi antikancerogenih spojeva
HRP20020175B1 (hr) N-heterociklički derivati kao inhibitori nos
DK328579A (da) Alkylderivater af c-076 forbindelser og fremgangsmaade til fremstilling deraf
GEP19960655B (en) Method of preparing hydantoin n-methyl esters
EP0823413A3 (en) Benzoheterocyclic compounds
HUT63155A (en) Process for producing substituted taxane derivatives and pharmaceutical compositions comprising such compounds as active ingredient
WO2004071388A3 (en) Medicinal compounds
ES431059A1 (es) Procedimiento para la preparacion de nuevos n-(metoximetil - furilmetil)-6, 7-benzomorfanos y -morfinanos.
SE7602122L (sv) Nya piperazinyliminorifamyciner och sett att framstella desamma
PL378201A1 (pl) Sposób farmaceutyczny oraz związki wytwarzane tym sposobem
NO20001871L (no) Nye 3,6-hemiacetaler fra klassen 9a-azalider
CA2357038A1 (en) Medical compositions comprising 1,4-benzothiazepine derivatives for the treatment of atrial fibrillation
WO2004080408A3 (en) Method of treating cancer with azaspirane compositions
DE3171116D1 (en) Arylamine derivatives, process for their preparation and their use as microbicides
HUT50327A (en) Process for producing 2-square brackets open /piperidin-4-yl/-methyl square brackets closed-1,2,3,4-tetrahydro-isoquinoline derivatives and pharmaceutical compositions comprising same
EP0713873A3 (en) Aminocyclopentane derivative
NZ335105A (en) Process for alkylating hindered sulfonamides
EA199900156A1 (ru) Новые производные эритромицина, способ их получения и их применение в качестве медикаментов
EP0465659A4 (en) Piperazine compound, production thereof, and medicinal use thereof
GB2004885A (en) Indolopyrones
YU74501A (sh) Sinteza 3-amino-3-aril propionata
NO20002315D0 (no) Nye 1-aza-2-alkyl-6-aryl-cykloalkanforbindelser, fremgangsmÕte ved deres fremstilling og farmasøytiske sammensetninger inneholdende dem
EP1632228A4 (en) MEDICINAL COMPOSITION CONTAINING TRIAZOLE COMPOUND
ES428442A1 (es) Un procedimiento para la preparacion de derivados de 1, 2, 3, 4-tetrahidroisoquinoleina.
MX2023004137A (es) Compuestos aromaticos sustituidos y composiciones farmaceuticas de los mismos.

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
PPPP Transfer of rights

Owner name: OSI PHARMACEUTICALS, INC., US

B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20100322

Year of fee payment: 11

PBON Lapse due to non-payment of renewal fee

Effective date: 20110401